8th Annual USC Multi-Disciplinary Breast Cancer Symposium



Date & Location
Saturday, January 23, 2021, 7:30 AM - 3:00 PM, Virtual Conference

Credits
AMA PRA Category 1 Credits™ (6.50 hours), Non-Physician Attendance (6.50 hours)

Overview

This program will review the current state-of-the-art for breast cancer management, highlighting the key components of multi-disciplinary treatment to include genetics, diagnostic imaging, pathology, surgical oncology, medical oncology, and radiation oncology. The format of this program will consist of lectures by international experts in their fields.

The management of genetic risk will be presented, as the importance of pathogenic mutations and variants of uncertain significance have become more integral in treatment decisions. The use of MRI as a diagnostic tool for patients having neoadjuvant chemotherapy will be reinforced using data from the University of Southern California. Recent advances in oncoplastic surgery will be presented by one of the surgeons who developed the field. The radiation oncology topic covers the advances in partial breast and accelerated radiation techniques.

The understanding of the HER2 receptor continues to evolve, and the biology of the HER2 axis will be presented by one of the pioneers in our understanding of this phenomenon. Key talks in medical oncology will focus on HER2+ breast cancer therapeutics in the metastatic setting, the emergence of resistance to antiestrogen therapy, and the evolution of immunotherapy as a central theme in the treatment of triple-negative breast cancer.


Objectives
By the end of the course, participants will be able to:

  1. Assess the evolution of recent concepts of genetic risk for breast cancer.
  2. Outline the role of diagnostic MRI in neoadjuvant treatment.
  3. Evaluate patients as candidates for oncoplastic surgical procedures.
  4. Outline the biology of the HER2 axis and its role in treating metastatic cancer.
  5. Describe the role of CDK inhibitors in treating ER+ cancers.
  6. Review newer concepts in treatment of triple negative breast cancers, including immunotherapy.
  7. Describe the evolving role of radiation therapy to the breast and axilla, such as changes in dose/fractionation and technique.

Accreditation
The Keck School of Medicine of the University of Southern California is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Keck School of Medicine of the University of Southern California designates this Live Activity activity for a maximum of 6.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 


Additional Information

Cancellation Policy

Cancellations must be received by the USC Office of CME (fax or email) no less than 3 days (12:00 pm PST) before the course for a refund. In support of health care professionals' need for flexibility during COVID-19, cancellation fees are waived for a full refund. In the event of course cancellation by conference organizers, all registration fees will be fully refunded.

In the event of course cancellation, all registration fees will be fully refunded. USC will not refund any travel costs incurred.

Accessibility Statement
 
Keck School of Medicine Healthcare System is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the USC Office of CME at usccme@usc.edu.